Covaxin protects against Delta, Beta variants of COVID-19, says study
3 years, 7 months ago

Covaxin protects against Delta, Beta variants of COVID-19, says study

India TV News  

Bharat Biotech's Covaxin offers protection against the Delta as well as Beta variants of SARS-CoV-2, which causes Covid-19, a joint study by researchers from Pune's National Institute of Virology, the Indian Council of Medical Research and Bharat Biotech has found. The study evaluated the neutralisation potential of sera collected from 20 Covid-recovered cases and 17 people vaccinated with two doses of Covaxin against Beta and Delta variants and compared it with the prototype D614G variant. So the vaccine does offer protection against the two variants,” says Dr. Pragya Yadav from the Pune-based National Institute of Virology and the first author of the preprint. Researchers evaluated the neutralisation potential of people vaccinated with Covaxin and found that it offers protection against these two variants.

Variants Covid Delta Vaccine Beta Icmr Bharat Biotech Covaxin Study Neutralisation  sera  covid19  covaxin  beta  vaccine  delta  study  neutralisation  vaccines  variants  protects

History of this topic

COVID-19 variant KP.3.1.1 predominant in US as infections continue ticking up
4 months, 2 weeks ago

COVID-19 variant KP.3.1.1 predominant in US as infections continue ticking up

China Daily  

LOS ANGELES - The KP.3.1.1 COVID-19 variant, now the predominant SARS-CoV-2 variant circulating in the United States, has been causing increasing infections in the country, the latest data from the US Centers for Disease Control and Prevention showed. For the two-week period ending Aug 17, KP.3.1.1 is predicted to account for between 31 percent and 43 percent of COVID-19 clinical …

Covaxin side effects: Amid concerns of adverse events, should Covaxin takers be worried?
7 months, 3 weeks ago

Covaxin side effects: Amid concerns of adverse events, should Covaxin takers be worried?

Hindustan Times  

A team of researchers at BHU in a one-year follow-up study found out that nearly one-third of 926 individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI. Serious AESI, including stroke and Guillain-Barre syndrome, were reported in around one per cent of individuals as per the study. Serious AESI, including stroke and Guillain-Barre …

1 in 3 Covaxin takers reported adverse events, BHU study claims
7 months, 3 weeks ago

1 in 3 Covaxin takers reported adverse events, BHU study claims

Hindustan Times  

A one-year follow-up study conducted by researchers at Banaras Hindu University has found that nearly one-third of individuals who received Bharat Biotech's Covaxin reported 'adverse events of special interest'. Read: AstraZeneca Covid vaccine related to another rare but deadly blood clotting disorder Adverse Events of Special Interest: Around 33% of participants reported AESI, with new-onset skin and subcutaneous disorders, general …

BHU study: Over 30 per cent of Covaxin recipients report adverse events
7 months, 3 weeks ago

BHU study: Over 30 per cent of Covaxin recipients report adverse events

India TV News  

A recent study conducted by researchers at Banaras Hindu University revealed that over 30% of individuals who received Bharat Biotech's Covaxin reported adverse events. The one-year follow-up study, encompassing 926 participants, shed light on the long-term safety of the BBV152 vaccine, with serious adverse events of special interest such as stroke and Guillain-Barre syndrome reported in one per cent of …

COVID-19 vaccines: Much ado about known unknowns
8 months ago

COVID-19 vaccines: Much ado about known unknowns

The Hindu  

There are things we know that we don’t know. This risk was identified and flagged back in 2021; packaging was modified to insert information associated with the side effects; even the WHO wrote about it first in May 2021 and then in 2023.Read Bindu Shajan Perapaddan’s report on the rare vaccine side-effect is “no secret” and they are “well aware …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
8 months, 1 week ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns
8 months, 1 week ago

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

India TV News  

In response to recent concerns regarding potential rare side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical company has underscored its unwavering commitment to patient safety while affirming the vaccine's overall safety profile. This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, …

Covishield more effective than Covaxin: Study
10 months ago

Covishield more effective than Covaxin: Study

New Indian Express  

BENGALURU: Covishield vaccine had higher antibody response compared to Covaxin during the pandemic, according to a study by a consortium of 11 institutions led by scientists from the National Centre for Biological Sciences, Bengaluru. In all, 691 people aged between 18 and 45, mostly from Bengaluru and Pune, were part of the study.’Immunogenicity of SARS - CoV-2 vaccines Covaxin and …

What study on Covishield versus Covaxin vaccine reveals
10 months ago

What study on Covishield versus Covaxin vaccine reveals

The Hindu  

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences, has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin. The key findings state that Covishield, leveraging a virus vector to deliver …

New COVID variant JN.1: Health Ministry says no need for booster dose
1 year ago

New COVID variant JN.1: Health Ministry says no need for booster dose

The Hindu  

Following the Union Health Ministry direction that States be alert and prepared for any possible surge in COVID-19 cases following the emergence of the new variant JN.1, senior health officials said that there is no move to recommend administration of vaccine booster dose for India. India saw a single-day rise of 656 COVID-1 infections while the active cases have increased …

High Levels of Exposure to Covid Virus May Reduce Protection from Vaccination, Prior Infection: Study
1 year, 4 months ago

High Levels of Exposure to Covid Virus May Reduce Protection from Vaccination, Prior Infection: Study

News 18  

High levels of exposure to the SARS-CoV-2 virus may reduce or overcome the protection that COVID-19 vaccination and prior infection provides, according to a study conducted in the US. Hybrid immunity provided the highest level of protection, at 95 per cent and 71 per cent effectiveness, in residents without a documented exposure and with a cell exposure, respectively, according to …

High levels of exposure to Covid virus may reduce protection from vaccination, prior infection: Study
1 year, 4 months ago

High levels of exposure to Covid virus may reduce protection from vaccination, prior infection: Study

Hindustan Times  

High levels of exposure to the SARS-CoV-2 virus may reduce or overcome the protection that COVID-19 vaccination and prior infection provides, according to a study conducted in the US. Specifically, during the Delta wave, vaccination was 68 per cent effective at preventing infection in residents without a documented exposure but was just 26 per cent effective in residents with exposure …

At least single dose vaccine prior to COVID-19 infection provided 60% protection against post-discharge mortality: ICMR study
1 year, 4 months ago

At least single dose vaccine prior to COVID-19 infection provided 60% protection against post-discharge mortality: ICMR study

The Hindu  

At least one dose of vaccine prior to COVID-19 infection provided 60% protection against post-discharge mortality, an Indian Council of Medical Research study on factors related to mortality within one year after discharge in hospitalised COVID-19 patients has found. Overall, the study’s findings suggest that a post-discharge mortality rate of 6.5% in patients hospitalised for COVID-19 warrants a vigilant follow-up. …

Pre-Covid shots provided 60% protection against post-infection deaths: Study
1 year, 4 months ago

Pre-Covid shots provided 60% protection against post-infection deaths: Study

India Today  

The Indian Council of Medical Research, which studied the cause of death in people after recovering from Covid-19 infection, found that those who were vaccinated before contracting the virus had 60 per cent protection against post-discharge mortality. An expert team working at the National Clinical Registry for Covid evaluated factors related to post-discharge mortality during the first year after Covid, …

Studies show XBB.1.16 is not clinically more severe
1 year, 8 months ago

Studies show XBB.1.16 is not clinically more severe

Hindustan Times  

The XBB.1.16 sub-variant of the Omicron strain of the SARS-CoV-2 virus that causes Covid does not exhibit higher clinical severity according to preliminary results from laboratory studies being conducted in the country to know disease characteristics, according to people familiar with the matter. According to the World Health Organisation, mutations at position 478 of the SARS-CoV-2 spike protein have been …

COVID-19 survivors develop natural immunity against severe illnesses: Lancet
1 year, 10 months ago

COVID-19 survivors develop natural immunity against severe illnesses: Lancet

Live Mint  

Protection against COVID-19 re-infection is very high, found a study by The Lancet. For those who had at least one prior infection with COVID-19, natural immunity against severe illness was potent and enduring for all variations. Previous exposure to pre-Omicron variants significantly weakened natural immune defences against Omicron BA.1 reinfection. Also, the research reveals that the amount and duration of …

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose
1 year, 11 months ago

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose

News 18  

The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India, had recently written to the DCGI for the approval …

mRNA Covid-19 vaccines can increase serious adverse events? US researcher claims
1 year, 11 months ago

mRNA Covid-19 vaccines can increase serious adverse events? US researcher claims

India TV News  

A US-based researcher has claimed that the messenger RNA Covid-19 vaccine can increase serious adverse events in people, including sudden cardiac deaths. Joseph Fraiman, the lead author of the peer-reviewed research that re-analysed Pfizer & Moderna trials for mRNA Covid-19 vaccine, has tweeted: "I believe the mRNA Covid-19 vaccines need to be withdrawn". In another tweet, he mentioned that the …

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study
2 years ago

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study

News 18  

Neutralising antibody responses against the SARS-COV-2 virus and its variants of concern are higher among Covishield recipients than those who took the indigenously made Covaxin, according to a multi-centre study. Covishield elicited immune responses of higher magnitude and breadth than Covaxin in both seronegative individuals and seropositive individuals, across cohorts representing the pre-vaccination immune history of the majority of the …

No second Covid-19 booster dose required: Report
2 years ago

No second Covid-19 booster dose required: Report

Live Mint  

There is no need to take a second booster dose against Covid-19 infection, news agency ANI reported on Tuesday citing government sources. According to the data by the Union Health Ministry, a total of 220.11 crore vaccine doses have been administered in the country, of which 95.13 crore have taken the second dose while only 22.41 crore of the population …

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch
2 years ago

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch

Hindustan Times  

Around 250 million Covid vaccines manufactured by two major Hyderabad-based units – Biological E and Bharat Biotech – are ready for dispatch in the market as soon as orders are received. Nearly 200 million Corbevax vaccine of Biological E and 50 million of Bharat Biotech's Covaxin are stockpiled at the moment. Read| Covid drills at hospitals; case count remains low …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
2 years ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster
2 years ago

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster

News 18  

A single dose of Bharat Biotech’s intranasal vaccine iNCOVACC is now available on CoWin application for Rs 800, while Rs 325 has been fixed for purchase in government facilities. Provided that private hospitals are permitted to charge up to Rs 150 as an administrative charge for every dose of the Covid-19 vaccine, one dose of this vaccine developed on a …

Nasal vaccines to roll out in private hospitals soon
2 years ago

Nasal vaccines to roll out in private hospitals soon

Hindustan Times  

A new coronavirus vaccine used as a nasal spray will only be available at private health facilities and the Co-WIN platform was set to be tweaked on Friday to allow people to immediately begin booking shots, people aware of the matter said on Friday. On Thursday, India’s technical expert committee on immunization— National Technical Advisory Group on Immunisation —recommended the …

Indian Army issues advisory on Covid, asks defence personnel to take safety measures
2 years ago

Indian Army issues advisory on Covid, asks defence personnel to take safety measures

India TV News  

The Indian Army issued an advisory on Friday asking defence personnel to take up adequate measures to tackle COVID. The advisory asked them to take up measures such as the usage of face masks in closed or crowded places, practising hand sanitisation, and maintaining social distancing among others. Union Health Minister Dr Mansukh Mandaviya is set to hold a virtual …

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose
2 years ago

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose

News 18  

The Serum Institute of India has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for …

Bharat Biotech misstated Covaxin trial data
2 years, 1 month ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

COVID-19 vaccines offer significant protection against reinfection: Study
2 years, 1 month ago

COVID-19 vaccines offer significant protection against reinfection: Study

India TV News  

COVID-19 vaccine: A recent study revealed that people earlier infected with the SARS-CoV-2 virus still benefit from vaccination against COVID-19, gaining 60% to 94% protection against reinfection. “In our study, we find a significant vaccine effectiveness against SARS-CoV-2 reinfection, and this shows the importance of vaccination also for those who might be protected by natural immunity," said Katrine Finderup Nielsen …

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take
2 years, 2 months ago

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take

India TV News  

Highlights Covaxin lying with the firm are set to expire early next year There are no takers owing to poor demand, said company sources India reported 1,082 fresh COVID-19 cases on Saturday Covaxin news: Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers …

CORBEVAX offers better immunity as a heterologous booster shot
2 years, 2 months ago

CORBEVAX offers better immunity as a heterologous booster shot

Deccan Chronicle  

HYDERABAD: Heterologous booster shots have gained significance in light of the waning effect of vaccine doses, especially against different variants of the Covid-19 virus. There is an increase in the immune response to the administration of heterologous booster shots on two counts – first cellular immunity and second, neutralizing antibodies. Administering the CORBEVAX vaccine as a heterologous booster dose provides …

COVID-19: Corbevax to be given as boosters at vaccination centres from today
2 years, 4 months ago

COVID-19: Corbevax to be given as boosters at vaccination centres from today

Live Mint  

Hyderabad based-Biological E Ltd 's recently approved heterologous Covid-19 vaccine Corbevax to be available as a booster dose on the COWIN App in both public and private vaccination centres from 12 August, the firm said on 11 August. The Union Health Ministry approved Corbevax as India's first heterologous COVID-19 booster shot for 18 years and above after the six months …

Corbevax as Covid booster for adults from August 12. Check details
2 years, 4 months ago

Corbevax as Covid booster for adults from August 12. Check details

India Today  

In a boost to India’s fight against coronavirus, the government gave nod to Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Announcing the decision, Union Health minister Mansukh Mandaviya said, “Further Strengthening India's arsenal against Covid-19, Ministry of Health and Family Welfare approves Corbevax as precaution dose for those …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 5 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 5 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

Three myths about COVID-19 — and the biggest challenge that lies ahead
2 years, 5 months ago

Three myths about COVID-19 — and the biggest challenge that lies ahead

ABC  

As an immunologist with four decades of research on antibodies under my belt, I always felt like I had a pretty good handle on COVID-19. COVID-19 left me with a serious heart complication that occurs in 2 per cent of infected people, with the risk not diminished by immunisation or prior infection. Unfortunately, vaccination didn't seem to help: the cumulative …

CDC endorses more traditional Novavax COVID-19 shot
2 years, 5 months ago

CDC endorses more traditional Novavax COVID-19 shot

LA Times  

A dish with syringes containing the Novavax COVID-19 vaccine sits in a refrigerator ready for use. U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax — a more traditional kind of vaccine, health officials said Tuesday. The Novavax difference All of the vaccines used in the U.S. train the body to fight the …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 6 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study
2 years, 6 months ago

Over 42 lakh deaths in India prevented by COVID-19 vaccines in 2021: Lancet study

The Hindu  

COVID-19 vaccines prevented over 42 lakh potential deaths in India in 2021, said a study published in The Lancet Infectious Diseases journal, which based its findings on estimates of "excess" mortalities in the country during the pandemic. In the first year of the vaccination programme, 19.8 million out of a potential 31.4 million COVID-19 deaths were prevented worldwide, according to …

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech
2 years, 6 months ago

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech

The Hindu  

Bharat Biotech International Limited, on Friday, announced that COVID-vaccine Covaxin has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The company in its press release said that Bharat Biotech had conducted phase II/III, open-label, and multi-centre study to evaluate the safety, reactogenicity, and immunogenicity Covaxin in healthy children and adolescents in 2-18 years …

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech
2 years, 6 months ago

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech

Firstpost  

The clinical trial conducted in the paediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity Hyderabad: Bharat Biotech International Limited on Friday announced that its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects in phase II/III study. Bharat Biotech had conducted phase II/III, open-label, and multi-centre …

A ground plan for India’s COVID-19 response
2 years, 6 months ago

A ground plan for India’s COVID-19 response

The Hindu  

India’s daily new COVID-19 cases have crossed the 8,000-mark for the first time after more than 100 days. Clearly, while the concerns about another national wave are unfounded, the ongoing surge demands for a fresh approach to the COVID-19 pandemic response in India. Because of hybrid immunity in India with two shots of vaccines and three national COVID-19 waves which …

Covaxin Effective Against Omicron Variants, Says ICMR as Sub-variants Driving up US Surge Found in Maha, Tamil Nadu
2 years, 6 months ago

Covaxin Effective Against Omicron Variants, Says ICMR as Sub-variants Driving up US Surge Found in Maha, Tamil Nadu

News 18  

The administration of Covaxin as a booster dose enhances vaccine effectiveness against Covid-19’s Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found. “The evidence from the present study shows that Covaxin booster immunisation tends to broaden the protective immune response and reduces disease severity against the Delta and Omicron …

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin
2 years, 7 months ago

Corbevax gets DCGI nod as COVID-19 booster after two doses of Covishield or Covaxin

The Hindu  

Hyderabad-based Biological E. Limited ’s COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination of Covaxin or Covishield vaccines for restricted use in emergency situations. ‘’Recently, BE furnished its clinical trials data to the DCGI, …

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above
2 years, 7 months ago

Corbevax Gets DCGI Approval As Covid-19 Vaccine Booster Dose For 18 Years And Above

ABP News  

New Delhi: The Drug Controller General of India approved the Corbevax Covid-19 booster as heterologous Covid-19 booster dose for adults above the age of 18 years who got their primary Covid-19 vaccination of Covishield or Covaxin administered six months before, reported news agency ANI. Recently, BE has furnished its clinical trials data to the DCGI who after a detailed evaluation …

Corbevax Gets Green Light From Drug Regulator As Covid Booster Dose for Adults
2 years, 7 months ago

Corbevax Gets Green Light From Drug Regulator As Covid Booster Dose for Adults

News 18  

In a first, Biological E’s Corbevax was on Saturday cleared by the Drug Control General of India as a heterologous Covid-19 booster dose for adults. Corbevax can now be administered as a booster dose to individuals aged 18 years and above after six months of administration of primary vaccination of Covaxin or Covishield vaccines. This approval reflects once again the …

Germany recognises Bharat Biotech's Covaxin for travel from June 1
2 years, 7 months ago

Germany recognises Bharat Biotech's Covaxin for travel from June 1

India TV News  

Highlights WHO in November last year issued an emergency use listing for Covaxin The step added a growing portfolio of vaccines validated for the prevention of COVID-19 WHO's EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines Germany has recognised the WHO-listed Bharat Biotech's COVID vaccine Covaxin, for travel to the country starting June 1. World Health Organization …

Mix and match of Covid vaccine for booster shots unlikely to be allowed: Report
2 years, 7 months ago

Mix and match of Covid vaccine for booster shots unlikely to be allowed: Report

Live Mint  

The government may not allow the administration of a precaution Covid-19 dose that is different from the one used for primary vaccination, reported news agency PTI, quoting sources, on Thursday. This comes in light of a recent study by the Christian Medical College Vellore, which showed that a booster dose of Covishield after primary vaccination with Covaxin gives 6 to …

COVID: Over 2,900 new pandemic cases, 32 fatalities in last 24 hours; active cases rise to 16,279
2 years, 8 months ago

COVID: Over 2,900 new pandemic cases, 32 fatalities in last 24 hours; active cases rise to 16,279

India TV News  

Highlights Total active cases of COVID in India have rose to 16,279 today The total death toll in the country is now at 5,23,654 The daily positivity rate is 0.58 per cent on April 27 COVID-19 India News Updates : India recorded 2,927 new cases of the novel coronavirus, along with 32 deaths due to the infection in the past …

Discover Related